Get the Stockscreener App
35.31
1.64%
-0.59
Atricure Inc stock is traded at $35.31, with a volume of 398.42K.
It is down -1.64% in the last 24 hours and up +11.63% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$35.90
Open:
$35.92
24h Volume:
398.42K
Relative Volume:
0.73
Market Cap:
$1.75B
Revenue:
$447.57M
Net Income/Loss:
$-38.92M
P/E Ratio:
-42.54
EPS:
-0.83
Net Cash Flow:
$-1.15M
1W Performance:
+2.62%
1M Performance:
+11.63%
6M Performance:
-13.88%
1Y Performance:
+64.31%
1-Day Range:
$35.16
$36.44
1-Week Range:
$34.51
$37.80
52-Week Range:
$20.44
$43.11
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
35.31 | 1.82B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
470.08 | 169.94B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
193.50 | 49.41B | 21.39B | 1.59B | 2.55B | 5.56 |
|
RMD
Resmed Inc
|
283.90 | 41.12B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ALC
Alcon Inc
|
85.75 | 41.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
240.98 | 17.06B | 2.90B | 467.20M | 306.90M | 6.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure, Inc. : Positioned for Growth in Surgical Afib Solutions - MarketScreener
AtriCure Inc. stock prediction for this weekFree AI Screening for Swing Trade Picks - Newser
Using Bollinger Bands to evaluate AtriCure Inc.Real-Time Entry Signals for Top Stocks - Newser
What makes AtriCure Inc. stock price move sharplySwing Gain Strategy with Entry Forecast - Newser
Visual analytics tools that track AtriCure Inc. performanceEarnings Report Summary with Market Impact - Newser
Atricure Director Makes a Significant Stock Sale! - TipRanks
What technical models suggest about AtriCure Inc.’s comebackOversold Opportunity Scanner with RSI Data - Newser
AtriCure (ATRC) Q2 2025 Earnings Call Transcript - Mitrade
Atricure’s CSO Makes a Strategic Stock Move! - TipRanks
How AtriCure Inc. stock performs during market volatilityPredictive Screener for Daily Trade Watch - Newser
AtriCure CSO Doraiswamy sells $91k in stock By Investing.com - Investing.com Australia
AtriCure CSO Doraiswamy sells $91k in stock - Investing.com
Candlestick signals on AtriCure Inc. stock todayFree Technical Entry Strategy for Beginners - Newser
Momentum Indicator Shows Bearish Divergence in AtriCure Inc.Beginner Friendly Stock Selection Guide Updated - beatles.ru
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $42 to $60 - 富途牛牛
Eighteen-Month LeAAPS Trial Enrollment Completed - Medical Product Outsourcing
Building trade automation scripts for AtriCure Inc.Momentum-Based Prediction for Quick Returns - Newser
Wall Street Zen Upgrades AtriCure (NASDAQ:ATRC) to Buy - Defense World
Why AtriCure Inc. stock attracts strong analyst attentionReal Trader Watchlist with Entry Targets - Newser
What drives AtriCure Inc. stock priceMaximize gains with professional stock picks - Jammu Links News
When is AtriCure Inc. stock expected to show significant growthAccelerated investment success - Jammu Links News
What catalysts could drive AtriCure Inc. stock higher in 2025Powerful profit generation - Jammu Links News
How many analysts rate AtriCure Inc. as a “Buy”Capitalize on emerging market sectors - Jammu Links News
AtriCure Inc. Stock Analysis and ForecastTriple-digit wealth increases - Jammu Links News
How strong is AtriCure Inc. company’s balance sheetAchieve consistent double-digit growth - Jammu Links News
What are the latest earnings results for AtriCure Inc.Consistent triple returns - Jammu Links News
Is AtriCure Inc. a good long term investmentBuild wealth with proven stock investing tactics - Jammu Links News
What is the dividend policy of AtriCure Inc. stockUnlock powerful trading tools for investors - Jammu Links News
What are AtriCure Inc. company’s key revenue driversCapitalize on emerging market sectors - Jammu Links News
How volatile is AtriCure Inc. stock compared to the marketSuperior return velocity - Jammu Links News
What is the risk reward ratio of investing in AtriCure Inc. stockAchieve rapid portfolio growth with expert help - Jammu Links News
Bollinger Bands Show Potential Breakout in AtriCure Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
Can AtriCure Inc. Escape Recent Bear ChannelReal Profit Trade Plan Suggestions Shared Widely - metal.it
AtriCure Rings the Opening Bell - Nasdaq
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
AtriCure Reports Strong Q2 Earnings with Record Growth - The Globe and Mail
Is AtriCure Inc. a growth stock or a value stockChart Pattern Updates With High Returns - Jammu Links News
AtriCure 2025 Q2 Earnings Beats Expectations with 22.7% Net Income Improvement - AInvest
AtriCure, Inc. (NASDAQ:ATRC) Q2 2025 Earnings Call Transcript - Insider Monkey
AtriCure Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Envestnet Asset Management Inc. Boosts Holdings in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure, Inc. SEC 10-Q Report - TradingView
Numerous AtriCure Insiders Sold Stock: Not A Positive Omen - simplywall.st
Needham raises AtriCure stock price target to $45 on strong Q2 results - Investing.com Canada
Needham raises AtriCure stock price target to $45 on strong Q2 results By Investing.com - Investing.com South Africa
AtriCure stock price target raised to $53 from $51 at Canaccord Genuity - Investing.com Canada
AtriCure stock price target raised to $45 from $44 at Needham - Investing.com Australia
AtriCure Stock Soars 10.4% on Strong Q2 Revenue Growth - AInvest
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Benzinga
JMP reiterates Market Outperform rating on AtriCure stock after strong Q2 - Investing.com Australia
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):